NewsRoom Articles - Page 33 of 115 - CanadianCannabisWire

ThursdaySep 09, 2021 1:27 pm

Flora Growth Corp. (NASDAQ: FLGC) Inks €2M Investment in Hoshi As Part of its European Expansion Plan

Flora closed a €2 million investment in Hoshi International Inc., fulfilling the earlier-announced LOI back in June 2021 This move is set to capitalize on Hoshi’s strong European presence, its technical know-how along with its understanding of the European market Hoshi acknowledged the investment with the announcement that it would work together with Flora to bring to market finished product formats from Flora’s brand portfolio Flora referred to this investment as the first of many steps by the company to advance its plans to launch products across the world On August 24, 2021, Flora Growth (NASDAQ: FLGC) announced closing a…

ThursdaySep 09, 2021 12:57 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference

Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream As…

WednesdaySep 08, 2021 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) is Changing Absorption of Fat-Soluble Compounds Through Patented DehydraTECH(TM) Technology

Lexaria Bioscience Corp. and its patented DehydraTECH technology promote a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing DehydraTECH is sub-licensed to other companies in select countries, and is in close collaboration with the largest R&D organization in Canada, the National Research Council, since January 2017 The technology is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions DehydraTECH-enabled drugs offer multiple benefits, including faster delivery, increased bioavailability, increased brain absorption, improved drug…

ThursdaySep 02, 2021 12:19 pm

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Ideally Situated in Burgeoning Cannabis Beverage Sector

EMR report projects that North America is likely to be fastest, largest marketplace for cannabis beverages Cannabis beverage industry projected to grow at CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026 BevCanna manufactures its own beverage product lines, offers white-label services to companies looking for the highest-quality products available North America will be a leader in the global cannabis beverage market, according to a recent Expert Market Research (“EMR”) report (https://cnw.fm/KFpSc). This projection bodes well for BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products…

WednesdaySep 01, 2021 11:21 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets with Drug Delivery Technology

Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective The company also released partial results from a human clinical study evaluating DehydraTECH-processed CBD for potential application against hypertension, which evidenced a rapid and sustained drop in blood pressure Growing hypertension and antiviral therapeutics market represent a potential win for Lexaria In July, Lexaria Bioscience (NASDAQ: LEXX), a drug delivery technology…

FridayAug 27, 2021 10:45 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference

The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants In addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is awaiting the answer to Phase II trial applications in various countries Dedicated to delivering new therapeutic alternatives as a treatment for conditions with a high unmet medical need, InMed Pharmaceuticals (NASDAQ: INM) is…

FridayAug 27, 2021 10:17 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Set to Announce Q2 2021 Results on August 30, 2021

Red White & Bloom Brands Inc. is set to release its Q2 2021 financial results on Monday, August 30, 2021 The announcement will also be followed by an update on the company’s asset purchases, accompanying notes along with management discussion and analysis Q1 2021 saw outstanding performance for the company, with the CEO announcing intentions to finalize its revised asset purchase of the Michigan investee The August 30 announcement will give an update to this and more investment decisions for Q2 2021 On July 27, 2021, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) announced its 2021 1st quarter…

WednesdayAug 25, 2021 11:08 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids InMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sources IntegraSyn’s ability to increase yields may ultimately help InMed to achieve a profitable means of producing cannabinol (“CBN”) and other lesser-known cannabinoids at commercial scales To date, GW Pharma’s Epidiolex is the only cannabis-derived product to achieve FDA approval as a pharmaceutical, and the company’s multi-million-dollar revenues demonstrate the potential returns a pharmaceutical-level drug can achieve British Columbia, Canada-based InMed Pharmaceuticals…

WednesdayAug 25, 2021 9:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Completes Acquisition of Apopka Cultivation Facility Further Expanding Florida Footprint

Red White & Bloom Inc. recently completed the acquisition of an operational 45,000 square-foot greenhouse situated on 4.7 acres of land in Apopka, Florida The acquisition comes less than four months after the company closed the purchase of a property in Sanderson, Florida RWB is intent on expanding its cultivation footprint in Florida as it also seeks to grow the number of retail stores in the state The Apopka facility will add near term cultivation capacity as RWB waits for the Sanderson facility to become operational A little less than four months after completing the acquisition of a property in…

TuesdayAug 24, 2021 10:40 am

Podcast Notes Blood Pressure Drug Delivery Trial Successes of Innovative Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology

Lexaria Bioscience is a drug delivery technology innovator whose flagship technology, DehydraTECH(TM), provides a means of enhancing substances’ delivery time to increase their effectiveness without adverse effects A new podcast by NetworkNewsAudio highlights DehydraTECH’s successes in trials that measure blood pressure reduction using DehydraTECH-enhanced CBD in comparison with generic controls The DehydraTECH technology is also being analyzed for effectiveness in combatting inflammatory conditions, viral illnesses and alternatives to the lung-harming effects of smoking The company’s most recent filing with the SEC notes that its revenues more than doubled between May 2020 and May 2021, driven largely by product sales and…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000